This report was first published by Endpoints News. To see the original version, click here
Johnson & Johnson will pay $3.05 billion in cash to buy Halda Therapeutics, a Connecticut biotech working on a new class of oral medicines to tame cancer.
The deal for Halda comes just a month after the startup released its first batch of clinical data in prostate cancer. The biotech is working on small molecule drugs called regulated induced proximity targeting chimeras. Halda’s lead drug, HLD-0915, targets both the androgen receptor and BRD4, a protein key to controlling the genome.
您已閱讀59%（578字），剩余41%（399字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。